AAO 2023: Bausch + Lomb vice president gives update on 3 new technologies
November 7th 2023Anthony Wallace, BS, MBA, vice president and general manager of the surgical business at Bausch + Lomb North America spoke with Ophthalmology Times about 3 new technologies the company launched at this year's American Academy of Ophthalmology meeting.
Clinical characteristics and progression of Geographic Atrophy in a Japanese population
November 7th 2023This retrospective, multicenter, observational study examined Japanese patients with GA to determine the clinical characteristics and GA progression rate associated with AMD in an Asian population.
AAO 2023: Unpacking the diverse approaches in dry AMD research
November 6th 2023Peter K. Kaiser, MD, shares a promising outlook for patients with dry age-related macular degeneration, with innovative therapies in development that have the potential not only to prevent vision loss but also improve visual acuity.
AAO 2023: Alcon spotlights technology in San Francisco
November 5th 2023At the 127th American Academy of Ophthalmology annual meeting in San Francisco, Alcon revealed the full U.S. commercial availability of its cloud-based cataract planner, building on its leading image-guided clinic to OR connectivity.
AAO 2023: Apellis unveils data from GALE extension study
November 5th 2023According to the study, detailed in presentations at the American Academy of Ophthalmology’s annual meeting in San Francisco, pegcetacoplan injection reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study.
AAO 2023: Do women bear a greater burden for blindness and vision loss in the United States?
November 4th 2023At this year's American Academy of Ophthalmology meeting, Mary Elizabeth Hartnett, MD, of the Byers Eye Institute at Stanford University presented on gender disparities in vision loss and blindness.
AAO 2023: OTT166 progress: OcuTerra's diabetic retinopathy treatment
November 3rd 2023Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.